Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cardiology Reviews
  4. Volume 21, Issue 3
  5. Article
Volume 21, Issue 3
  • ISSN: 1573-403X
  • E-ISSN: 1875-6557

Abstract

Iron deficiency anemia (IDA) is highly prevalent among individuals with heart failure (HF), impacting 40-70% of patients and serving as a significant prognostic indicator. Linked with oxidative metabolism and myocardial cell damage, IDA exacerbates HF symptoms, including reduced exercise capacity, diminished quality of life, and heightened cardiovascular morbidity. This review explores the diagnosis, treatment, clinical outcomes, prognostic indicators, and forthcoming challenges associated with IDA in HF patients. Crucially, addressing IDA in HF is critical for enhancing prognosis, including clinical outcomes, quality of life, hospitalizations, and survival rates. While oral iron therapy shows efficacy in reducing mortality and hospitalizations, it falls short in improving exercise capacity and quality of life, often deterring patients due to side effects. In contrast, intravenous (IV) iron therapy is highly effective in enhancing hematological parameters, functional capacity, and reducing HF hospitalizations. Optimizing IV iron dosing based on individual patient characteristics is essential for balancing treatment efficacy and adverse effects. Emphasizing individualized approaches, with IV iron emerging as a superior option, underscores the necessity for ongoing research to refine dosing strategies and explore novel therapies. Compliance remains paramount for positive outcomes with IDA treatment, with oral supplementation being cost-effective and easily accessible. However, parenteral supplementation proves beneficial for patients intolerant to oral therapy. Addressing IDA through tailored interventions, including oral or parenteral supplementation, is pivotal in averting complications and improving outcomes in HF patients. This paper consolidates insights into the diagnosis, treatment, impact, pathophysiology, clinical outcomes, research gaps, and future directions concerning IDA in HF patients, drawing on extensive literature to offer a comprehensive understanding of this critical issue.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X331380241111091452
2025-01-03
2025-05-25

  • From This Site

    /content/journals/ccr/10.2174/011573403X331380241111091452
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LoncarG. ObradovicD. ThieleH. von HaehlingS. LainscakM. Iron deficiency in heart failure.ESC Heart Fail.2021842368237910.1002/ehf2.13265 33932115
     [Google Scholar]
  2. SindoneA. DoehnerW. ManitoN. Practical guidance for diagnosing and treating iron deficiency in patients with heart failure: Why, Who and How?J. Clin. Med.20221111297610.3390/jcm11112976 35683366
     [Google Scholar]
  3. SingerC.E. VasileC.M. PopescuM. Role of iron deficiency in heart failure-clinical and treatment approach: An overview.Diagnostics (Basel)202313230410.3390/diagnostics13020304 36673114
     [Google Scholar]
  4. ChopraV.K. AnkerS.D. Anaemia, iron deficiency and heart failure in 2020: Facts and numbers.ESC Heart Fail.2020752007201110.1002/ehf2.12797 32602663
     [Google Scholar]
  5. Gluba-BrzózkaA. FranczykB. OlszewskiR. RyszJ. The influence of inflammation on anemia in CKD patients.Int. J. Mol. Sci.202021372510.3390/ijms21030725 31979104
     [Google Scholar]
  6. ShaikhH. HashmiM.F. AeddulaN.R. Anemia of chronic kidney disease.In: StatPearls.StatPearls Publishing2024
     [Google Scholar]
  7. YangZ. WangD. ZhangC. The applications of gold nanoparticles in the diagnosis and treatment of gastrointestinal cancer.Front. Oncol.20221181932910.3389/fonc.2021.819329 35127533
     [Google Scholar]
  8. MillerJ.L. Iron deficiency anemia: A common and curable disease.Cold Spring Harb. Perspect. Med.201337a01186610.1101/cshperspect.a011866 23613366
     [Google Scholar]
  9. ShiM. DongZ. ZhaoK. Novel insights into exhaustive exercise-induced myocardial injury: Focusing on mitochondrial quality control.Front. Cardiovasc. Med.20229101563910.3389/fcvm.2022.1015639 36312267
     [Google Scholar]
  10. KempC.D. ConteJ.V. The pathophysiology of heart failure.Cardiovasc. Pathol.201221536537110.1016/j.carpath.2011.11.007 22227365
     [Google Scholar]
  11. HidronH. VogenthalerN. Santos-PreciadoJ.I. Cardiac involvement with parasitic infections.Clin. Microbiol. Rev.2010232324349
     [Google Scholar]
  12. JankowskaE.A. von HaehlingS. AnkerS.D. MacdougallI.C. PonikowskiP. Iron deficiency and heart failure: Diagnostic dilemmas and therapeutic perspectives.Eur. Heart J.2013341181682910.1093/eurheartj/ehs224 23100285
     [Google Scholar]
  13. ClelandJ.G.F. ZhangJ. PellicoriP. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure.JAMA Cardiol.20161553954710.1001/jamacardio.2016.1161 27439011
     [Google Scholar]
  14. HegdeN. RichM.W. GayomaliC. The cardiomyopathy of iron deficiency.Tex. Heart Inst. J.2006333340344 17041692
     [Google Scholar]
  15. von HaehlingS. EbnerN. EvertzR. PonikowskiP. AnkerS.D. Iron deficiency in heart failure.JACC Heart Fail.201971364610.1016/j.jchf.2018.07.015 30553903
     [Google Scholar]
  16. FurrerR. Remodeling of metabolism and inflammation by exercise ameliorates tumor-associated anemia.Sci. Adv.2021737eabi4852
     [Google Scholar]
  17. PetersC.J. HanffT.C. GenuardiM.V. Safety and effectiveness of intravenous iron therapy in patients supported by durable left ventricular assist devices.J. Clin. Med.20221113390010.3390/jcm11133900 35807184
     [Google Scholar]
  18. MasiniG. GrahamF.J. PellicoriP. Criteria for iron deficiency in patients with heart failure.J. Am. Coll. Cardiol.202279434135110.1016/j.jacc.2021.11.039 35086656
     [Google Scholar]
  19. McDonaghT. DamyT. DoehnerW. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: Putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice.Eur. J. Heart Fail.201820121664167210.1002/ejhf.1305 30311713
     [Google Scholar]
  20. AlnuwaysirR. HoesM. van VeldhuisenD. van der MeerP. Grote BeverborgN. Iron deficiency in heart failure: Mechanisms and pathophysiology.J. Clin. Med.202111112510.3390/jcm11010125 35011874
     [Google Scholar]
  21. Kaluzna-OleksyM. SawczakF. KukfiszA. Appetite and nutritional status as potential management targets in patients with heart failure with reduced ejection fraction-the relationship between echocardiographic and biochemical parameters and appetite.J. Pers. Med.202111763910.3390/jpm11070639 34357106
     [Google Scholar]
  22. TakadaT. JujoK. InagakiK. Nutritional status during hospitalization is associated with the long-term prognosis of patients with heart failure.ESC Heart Fail.2021865372538210.1002/ehf2.13629 34598321
     [Google Scholar]
  23. HurrellR. EgliI. Iron bioavailability and dietary reference values.Am. J. Clin. Nutr.20109151461S1467S10.3945/ajcn.2010.28674F 20200263
     [Google Scholar]
  24. MoustarahF. DaleyS.F. Dietary iron.In: StatPearls.StatPearls Publishing2024
     [Google Scholar]
  25. Mohd AtanF.N.E. Wan Mohd SamanW.A. KamsaniY.S. KhalidZ. Abdul RahmanA. TMPRSS6 gene polymorphisms associated with iron deficiency anaemia among global population.Egypt. J. Med. Hum. Genet.202223114710.1186/s43042‑022‑00362‑1
     [Google Scholar]
  26. Clinical Liver Disease Available from: https://journals.lww.com/cld/fulltext/2020/11000/acg_clinical_guideline__hereditary_hemochromatosis.1.aspx
  27. NaitoY. TsujinoT. FujimoriY. Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats.J. Hypertens.201129474174810.1097/HJH.0b013e3283434784 21191310
     [Google Scholar]
  28. AnandI.S. GuptaP. Anemia and iron deficiency in heart failure.Circulation20181381809810.1161/CIRCULATIONAHA.118.030099 29967232
     [Google Scholar]
  29. MuQ. ChenL. GaoX. The role of iron homeostasis in remodeling immune function and regulating inflammatory disease.Sci. Bull. (Beijing)202166171806181610.1016/j.scib.2021.02.010 36654387
     [Google Scholar]
  30. DouwesR.M. Chronic use of proton-pump inhibitors and iron status in renal transplant recipients.J. Clin. Med.2019891382
     [Google Scholar]
  31. JelkmannW. Physiology and pharmacology of erythropoietin.Transfus. Med. Hemother.201340530230910.1159/000356193 24273483
     [Google Scholar]
  32. MiyauchiK. NakaiT. SaitoS. Renal interstitial fibroblasts coproduce erythropoietin and renin under anaemic conditions.EBioMedicine20216410320910.1016/j.ebiom.2021.103209 33508746
     [Google Scholar]
  33. GoyalA. CusickA.S. ThielemierB. ACE Inhibitors.In: StatPearls.StatPearls Publishing2024
     [Google Scholar]
  34. KimY.C. MungunsukhO. DayR.M. Erythropoietin regulation by angiotensin II.Vitam. Horm.2017105577710.1016/bs.vh.2017.02.001
     [Google Scholar]
  35. KatoH. IshidaJ. MatsusakaT. Erythropoiesis and blood pressure are regulated via AT1 receptor by distinctive pathways.PLoS One2015106e012948410.1371/journal.pone.0129484 26107632
     [Google Scholar]
  36. ZhangH. JamiesonK.L. GrenierJ. Myocardial iron deficiency and mitochondrial dysfunction in advanced heart failure in humans.J. Am. Heart Assoc.20221111e02285310.1161/JAHA.121.022853 35656974
     [Google Scholar]
  37. RochaB.M.L. CunhaG.J.L. Menezes FalcãoL.F. The burden of iron deficiency in heart failure.J. Am. Coll. Cardiol.201871778279310.1016/j.jacc.2017.12.027 29447741
     [Google Scholar]
  38. DietzJ.V. FoxJ.L. KhalimonchukO. Down the iron path: Mitochondrial iron homeostasis and beyond.Cells2021109219810.3390/cells10092198 34571846
     [Google Scholar]
  39. KarwiQ.G. UddinG.M. HoK.L. LopaschukG.D. Loss of metabolic flexibility in the failing heart.Front. Cardiovasc. Med.201856810.3389/fcvm.2018.00068 29928647
     [Google Scholar]
  40. AgarwalA. Shah. Anemia associated with chronic heart failure: current concepts.Clin. Interv. Aging2013811112210.2147/CIA.S27105 23403618
     [Google Scholar]
  41. JimenezK. Kulnigg-DabschS. GascheC. Management of iron deficiency anemia.Gastroenterol. Hepatol. (N. Y.)2015114241250 27099596
     [Google Scholar]
  42. JankowskaE.A. TkaczyszynM. DrozdM. PonikowskiP. Monitoring of iron status in patients with heart failure.Eur. Heart J. Suppl.201921Suppl. MM32M3510.1093/eurheartj/suz231 31908613
     [Google Scholar]
  43. Del PintoR. FerriC. Iron deficiency in heart failure: Diagnosis and clinical implications.Eur. Heart J. Suppl.202224Suppl. II96I9910.1093/eurheartjsupp/suac080 36380788
     [Google Scholar]
  44. GattermannN. MuckenthalerM.U. KulozikA.E. MetzgerothG. HastkaJ. The evaluation of iron deficiency and iron overload.Dtsch. Arztebl. Int.20211184984785610.3238/arztebl.m2021.0290 34755596
     [Google Scholar]
  45. RuschJ.A. van der WesthuizenD.J. GillR.S. LouwV.J. Diagnosing iron deficiency: Controversies and novel metrics.Baillieres. Best Pract. Res. Clin. Anaesthesiol.202337445146710.1016/j.bpa.2023.11.001
     [Google Scholar]
  46. NemethE. GanzT. Anemia of inflammation.Hematol. Oncol. Clin. North Am.2014284671681vi.10.1016/j.hoc.2014.04.005 25064707
     [Google Scholar]
  47. Grote BeverborgN. KlipI.J.T. MeijersW.C. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients.Circ. Heart Fail.2018112e00451910.1161/CIRCHEARTFAILURE.117.004519 29382661
     [Google Scholar]
  48. DignassA. Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions.Int. J. Chronic Dis.201820189394060
     [Google Scholar]
  49. MozosI. Mechanisms linking red blood cell disorders and cardiovascular diseases.Biomed Res. Int.20152015682054
     [Google Scholar]
  50. RohrM. BrandenburgV. Brunner-La RoccaH.P. How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome.Eur. J. Med. Res.20232811510.1186/s40001‑022‑00922‑6 36617559
     [Google Scholar]
  51. ShamsiA. CannataA. PiperS. BromageD.I. McDonaghT.A. Treatment of iron deficiency in heart failure.Curr. Cardiol. Rep.202325764966110.1007/s11886‑023‑01889‑4 37329419
     [Google Scholar]
  52. SuryaniL.D. RaharjoS.B. SagitaR. Oral ferrous sulphate improves functional capacity on heart failure patients with iron deficiency anemia.Glob. Heart20221718110.5334/gh.1151 36578916
     [Google Scholar]
  53. MeiZ. ChenJ. LuoS. JinL. LiuQ. ChenY. Comparative efficacy of intravenous and oral iron supplements for the treatment of iron deficiency in patients with heart failure: A network meta-analysis of randomized controlled trials.Pharmacol. Res.202218210634510.1016/j.phrs.2022.106345 35810949
     [Google Scholar]
  54. YunL. YuMei Z, Bn V, Tang Q, Feng C. The efficacy, safety, and economic outcomes of using ferric derisomaltose for the management of iron deficiency in China: A rapid health technology assessment.Cureus20231511e4871710.7759/cureus.48717 38094535
     [Google Scholar]
  55. BhandariS. PereiraD.I.A. ChappellH.F. DrakesmithH. Intravenous irons: From basic science to clinical practice.Pharmaceuticals (Basel)20181138210.3390/ph11030082 30150598
     [Google Scholar]
  56. MentzR.J. GargJ. RockholdF.W. Ferric carboxymaltose in heart failure with iron deficiency.N. Engl. J. Med.20233891197598610.1056/NEJMoa2304968 37632463
     [Google Scholar]
  57. PonikowskiP. KirwanB.A. AnkerS.D. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial.Lancet2020396102661895190410.1016/S0140‑6736(20)32339‑4 33197395
     [Google Scholar]
  58. KalraP.R. ClelandJ.G.F. PetrieM.C. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.Lancet2022400103692199220910.1016/S0140‑6736(22)02083‑9 36347265
     [Google Scholar]
  59. Effect of IV iron in patients with heart failure with preserved ejection fraction (FAIR-HFpEF).NCT030745912024
     [Google Scholar]
  60. Gómez-RamírezS. ShanderA. SpahnD.R. Prevention and management of acute reactions to intravenous iron in surgical patients.Blood Transfus.201917213714510.2450/2018.0156‑18 30418128
     [Google Scholar]
  61. TangvarasittichaiS. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.World J. Diabetes20156345648010.4239/wjd.v6.i3.456 25897356
     [Google Scholar]
  62. EhlkenB. NathellL. GohlkeA. BocukD. ToussiM. WohlfeilS. Evaluation of the reported rates of severe hypersensitivity reactions associated with ferric carboxymaltose and iron (III) isomaltoside 1000 in Europe based on data from eudravigilance and VigiBase™ between 2014 and 2017.Drug Saf.201942346347110.1007/s40264‑018‑0769‑5 30535629
     [Google Scholar]
  63. KennedyN.A. AchebeM.M. BiggarP. PöhlmannJ. PollockR.F. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.Int. J. Clin. Pharm.202345360461210.1007/s11096‑023‑01548‑2 37010731
     [Google Scholar]
  64. DochertyK.F. WelshP. VermaS. Iron deficiency in heart failure and effect of dapagliflozin: Findings from DAPA-HF.Circulation20221461398099410.1161/CIRCULATIONAHA.122.060511 35971840
     [Google Scholar]
  65. 2022 AHA/ACC/HFSA Guideline for the management of heart Failure: A report of the American college of cardiology/American Heart Association Joint Committee on clinical practice guidelines.JACC.20227917e263e42110.1016/j.jacc.2021.12.012
     [Google Scholar]
  66. MartensP. MintenL. DupontM. MullensW. The importance of dose optimisation in the treatment of iron deficiency in heart failure.Acta Cardiol.202075652052410.1080/00015385.2019.1625554 31184977
     [Google Scholar]
  67. JhundP.S. PetrieM.C. RobertsonM. Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy.JACC Heart Fail.20219751852710.1016/j.jchf.2021.04.005 34119470
     [Google Scholar]
  68. PunjS. GhafourianK. ArdehaliH. Iron deficiency and supplementation in heart failure and chronic kidney disease.Mol. Aspects Med.20207510087310.1016/j.mam.2020.100873 32753256
     [Google Scholar]
  69. MacdougallI.C. PonikowskiP. StackA.G. Ferric carboxymaltose in iron-deficient patients with hospitalized heart failure and reduced kidney function.Clin. J. Am. Soc. Nephrol.20231891124113410.2215/CJN.0000000000000223 37382961
     [Google Scholar]
  70. MacdougallI.C. WhiteC. AnkerS.D. Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL): Study design and baseline data.Am. J. Nephrol.201848426026810.1159/000493551 30304714
     [Google Scholar]
  71. LewisG.D. SemigranM.J. GivertzM.M. Oral iron therapy for heart failure with reduced ejection fraction.Circ. Heart Fail.201695e00034510.1161/CIRCHEARTFAILURE.115.000345 27140203
     [Google Scholar]
  72. OkonkoD.O. GrzesloA. WitkowskiT. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial.J. Am. Coll. Cardiol.200851210311210.1016/j.jacc.2007.09.036 18191732
     [Google Scholar]
  73. GutzwillerF.S. PfeilA.M. Comin-ColetJ. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.Int. J. Cardiol.201316843878388310.1016/j.ijcard.2013.06.045 23870642
     [Google Scholar]
  74. FilippatosG. FarmakisD. ColetJ.C. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: A subanalysis of the FAIR-HF trial.Eur. J. Heart Fail.201315111267127610.1093/eurjhf/hft099 23787722
     [Google Scholar]
  75. AnkerS.D. KhanM.S. ButlerJ. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta‐analysis.Eur. J. Heart Fail.20232571080109010.1002/ejhf.2860 37062867
     [Google Scholar]
  76. MentzR.J. AmbrosyA.P. EzekowitzJ.A. Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: Rationale and design.Circ. Heart Fail.2021145e00810010.1161/CIRCHEARTFAILURE.120.008100 34003690
     [Google Scholar]
  77. OguguaF.M. AguilarF.A. GamamA. Treating iron deficiency (ID) anemia in heart failure (HF) patients with IV iron: A meta-analysis.Cureus2023157e4189510.7759/cureus.41895 37581143
     [Google Scholar]
  78. JacobC. AlteversJ. BarckI. HardtT. BraunS. GreinerW. Retrospective analysis into differences in heart failure patients with and without iron deficiency or anaemia.ESC Heart Fail.20196484085510.1002/ehf2.12485 31286685
     [Google Scholar]
  79. CheemaB. AmbrosyA.P. KaplanR.M. Lessons learned in acute heart failure.Eur. J. Heart Fail.201820463064110.1002/ejhf.1042 29082676
     [Google Scholar]
  80. López-VilellaR. Donoso TrenadoV. Jover PastorP. Sánchez-LázaroI. Martínez DolzL. Almenar BonetL. Why iron deficiency in acute heart failure should be treated: A real-world clinical practice study.Life (Basel)20221211182810.3390/life12111828 36362983
     [Google Scholar]
  81. PonikowskiP. van VeldhuisenD.J. Comin-ColetJ. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency.Eur. Heart J.2015361165766810.1093/eurheartj/ehu385 25176939
     [Google Scholar]
  82. KaravidasA. TroganisE. LazarosG. Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open‐label, proof‐of‐concept study.Eur. J. Heart Fail.202123459359710.1002/ejhf.2092 33421230
     [Google Scholar]
  83. Cohen-SolalA. LeclercqC. DerayG. Iron deficiency: An emerging therapeutic target in heart failure.Heart2014100181414142010.1136/heartjnl‑2014‑305669 24957529
     [Google Scholar]
  84. RamptonD. FolkersenJ. FishbaneS. Hypersensitivity reactions to intravenous iron: Guidance for risk minimization and management.Haematologica201499111671167610.3324/haematol.2014.111492 25420283
     [Google Scholar]
  85. BanerjeeS. McCormackS. Intravenous iron preparations for patients undergoing elective surgery: A review of clinical effectiveness, cost-effectiveness, and guidelines.In: CADTH rapid response report: Summary with critical appraisal. Ottawa (ON):Canadian agency for drugs and technologies in health2019
     [Google Scholar]
  86. BehnoushA.H. KhalajiA. NaderiN. AshrafH. von HaehlingS. ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison.ESC Heart Fail.20231031531154410.1002/ehf2.14255 36460629
     [Google Scholar]
  87. LamC.S.P. DoehnerW. Comin-ColetJ. Iron deficiency in chronic heart failure: Case‐based practical guidance.ESC Heart Fail.20185576477110.1002/ehf2.12333 30073785
     [Google Scholar]
  88. HeidenreichP.A. BozkurtB. AguilarD. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines.Circulation202214518e895e103210.1161/CIR.0000000000001063 35363499
     [Google Scholar]
  89. BloorS.R. SchutteR. HobsonA.R. Oral iron supplementation-Gastrointestinal side effects and the impact on the gut microbiota.Microbiol. Res. (Pavia)202112249150210.3390/microbiolres12020033
     [Google Scholar]
  90. PiskinE. CianciosiD. GulecS. TomasM. CapanogluE. Iron absorption: Factors, limitations, and improvement methods.ACS Omega2022724204412045610.1021/acsomega.2c01833 35755397
     [Google Scholar]
  91. EmsT. St LuciaK. HueckerM.R. Biochemistry, iron absorption.In: StatPearls.StatPearls Publishing2024http://www.ncbi.nlm.nih.gov/books/NBK448204/
     [Google Scholar]
  92. CohenC.T. PowersJ.M. Nutritional strategies for managing iron deficiency in adolescents: Approaches to a challenging but common problem.Adv. Nutr.202415510021510.1016/j.advnut.2024.100215 38556251
     [Google Scholar]
  93. NguyenM. TadiP. Iron Supplementation.In: StatPearls.StatPearls Publishing2024
     [Google Scholar]
  94. SkolmowskaD. GłąbskaD. KołotaA. GuzekD. Effectiveness of dietary interventions to treat iron-deficiency anemia in women: A systematic review of randomized controlled trials.Nutrients20221413272410.3390/nu14132724 35807904
     [Google Scholar]
  95. CappelliniM.D. Comin-ColetJ. de FranciscoA. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management.Am. J. Hematol.201792101068107810.1002/ajh.24820 28612425
     [Google Scholar]
  96. CacoubP. ChoukrounG. Cohen-SolalA. Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action.J. Intern. Med.2022292454255610.1111/joim.13503 35466452
     [Google Scholar]
  97. GhamriR. AlsulamiH. Intravenous iron versus oral iron administration for the treatment of iron deficiency anemia: A patient-preference study.Cureus2024167e6550510.7759/cureus.65505 39188434
     [Google Scholar]
  98. RichardsT. BreymannC. BrookesM.J. Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice.Ann. Med.202153127428510.1080/07853890.2020.1867323
     [Google Scholar]
  99. KidoK BeaversCJ DulnuanK Management of iron deficiency in heart failure.JACC Heart Fail2024; S2213-1779(24): 00433-5.10.1016/j.jchf.2024.05.014 39001744
     [Google Scholar]
  100. AuerbachM. DelougheryT. Single-dose intravenous iron for iron deficiency: A new paradigm.Hematology (Am. Soc. Hematol. Educ. Program)201620161576610.1182/asheducation‑2016.1.57 27913463
     [Google Scholar]
  101. LucasS. GargM. Intravenous iron: An update.Intern. Med. J.2024541263410.1111/imj.16184 37490496
     [Google Scholar]
/content/journals/ccr/10.2174/011573403X331380241111091452
Loading
The Intersection of Heart Failure and Iron Deficiency Anemia: Diagnostic and Therapeutic Approaches
Curr. Cardiol. Rev. 21, E1573403X331380 (2025); https://doi.org/10.2174/011573403X331380241111091452
/content/journals/ccr/10.2174/011573403X331380241111091452
/content/journals/ccr/10.2174/011573403X331380241111091452
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): clinical outcomes; Heart failure; individualized approach; intravenous iron therapy; iron deficiency anemia; prognosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test